Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit .SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present a corporate update at the Piper Sandler 36th Annual Healthcare Conference, at 2:30 p.m. ET on Tuesday, December 3, 2024, in New York City.
旧金山，2024年11月25日（GLOBE NEWSWIRE）——开发旨在治疗癌症和炎症性疾病患者的靶向蛋白质调制药物的临床阶段生物制药公司Nurix Therapeutics, Inc.（纳斯达克股票代码：NRIX）今天宣布，Nurix总裁兼首席执行官亚瑟·桑德斯万博士将在派珀·桑德勒第36届年度医疗保健大会上介绍公司最新情况，美国东部时间2024年12月3日星期二下午2点30分，在纽约市。
The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available for 30 days after the event.
该活动将进行网络直播，可通过Nurix网站投资者部分的活动和演示下的链接进行访问。存档的网络直播将在活动结束后的30天内提供。
About Nurix Therapeutics, Inc.
关于 Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform, to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin-proteasome system to selectively decrease or increase cellular protein levels. Nurix's wholly owned, clinical stage pipeline includes targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit .
Nurix Therapeutics是一家临床阶段的生物制药公司，专注于基于调节细胞蛋白水平的创新小分子和抗体疗法的发现、开发和商业化，这是一种治疗癌症、炎症性疾病和其他具有挑战性的疾病的新方法。Nurix利用在E3连接酶方面的广泛专业知识以及专有的DNA编码库，建立了综合发现平台Deligase，以识别和推进针对E3连接酶的新型候选药物，E3连接酶是一种可以调节细胞内蛋白质的酶。Nurix的药物发现方法是利用或抑制泛素-蛋白酶体系统中E3连接酶的自然功能，以选择性地降低或增加细胞蛋白水平。Nurix的全资临床阶段产品线包括Bruton酪氨酸激酶的靶向蛋白降解剂（一种b细胞信号蛋白）和Casitas b系淋巴瘤原癌基因b的抑制剂，这是一种调节包括T细胞和Nk细胞在内的多种免疫细胞类型激活的E3连接酶。Nurix 总部位于加利福尼亚州旧金山。欲了解更多信息，请访问。
Contacts:
联系人：
Investors
投资者
Jason Kantor, Ph.D.
Nurix Therapeutics
ir@nurixtx.com
杰森·坎特博士
Nurix 疗法
ir@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
伊丽莎白·沃尔夫博士
惠尔豪斯生命科学顾问
lwolffe@wheelhouselsa.com
Media
媒体
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Aljanae Reynolds
惠尔豪斯生命科学顾问
areynolds@wheelhouselsa.com
